<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03235141</url>
  </required_header>
  <id_info>
    <org_study_id>ESSEX-AOS-PK-2001</org_study_id>
    <nct_id>NCT03235141</nct_id>
  </id_info>
  <brief_title>Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers</brief_title>
  <official_title>Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhuhai Essex Bio-Pharmaceutical Company Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Panacea Technology Co.，Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetic behavior of azithromycin eye drops in the tear with the
      original azithromycin eye drops, and evaluate the release behavior of both in the eye.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 48 patients will divided into group A and group B randomly . subjects of Group A
      will given the first test drug, elution after the control drug; Subjects of Group B will
      given the first control drug, elution given to the test drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>There are 8 subjects will be enrolled in pre-test, each subject was sampled in two eyes and each subject participated in two cycles of the trial. 8 subjects, 16 eyes participated in the study, 32 samples of tears total .
There are 48 subjects will divided into group A and group B randomly . subjects of Group A will given the first test drug, elution after the control drug; Subjects of Group B will given the first control drug, elution given to the test drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours</time_frame>
    <description>The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours，The AUC of the test drug and the control drug was calculated at the average concentration of each point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours</time_frame>
    <description>The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours，The Cmax of the test drug and the control drug was calculated at the average concentration of each point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>from the ICF signed to the end of the trial,through study completion, an average of 1 year</time_frame>
    <description>compared the laboratory test values before and after treatment,according to the study drug use, calculate the number of cases, the number of cases and the incidence of adverse reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>from the ICF signed to the end of the trial,through study completion, an average of 1 year</time_frame>
    <description>Any serious adverse events that occur during the clinical study, whether or not related to the drug should be collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>azithromycin eye drops by essex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AzaSite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin eye drops by essex</intervention_name>
    <description>azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),</description>
    <arm_group_label>azithromycin eye drops by essex</arm_group_label>
    <arm_group_label>AzaSite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin eye drops</intervention_name>
    <description>azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc</description>
    <arm_group_label>azithromycin eye drops by essex</arm_group_label>
    <arm_group_label>AzaSite</arm_group_label>
    <other_name>AzaSite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years old, male or female;

          -  BMI in the range of 19 to 28;

          -  eyes corrected visual acuity should be ≥ 1.0, intraocular pressure, slit lamp and
             fundus examination were normal, tear secretion function is normal;

          -  Good compliance and voluntarily signed consent.

        Exclusion Criteria:

          -  Have eye disease or systemic disease;

          -  physical examination, laboratory tests, ECG and chest X-ray examination abnormalities
             and has clinical significance;

          -  HBsAg, anti-HCV and HIV positive;

          -  those who used eye drops two weeks before the test and who used any dosage form of
             azithromycin;

          -  known to azithromycin or macrolide-related varieties of allergies or serious adverse
             reactions;

          -  need to wear contact lenses during the test;

          -  history of internal surgery or laser surgery history;

          -  participated in other drug clinical trials in the past three months;

          -  pregnant women and lactating women, or in the growth period without taking effective
             contraceptive measures, menstrual period women;

          -  mental illness or alcohol, history of drug abuse or inability to collaborate;

          -  Any other circumstances that the investigators consider are unfit to participate in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zhao, Doctor</last_name>
    <phone>+86-13911901818</phone>
    <email>XL_Zhao_YLJD@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siyang Ni, Doctor</last_name>
    <phone>+86-18911810275</phone>
    <email>grandnsy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wu</last_name>
      <phone>010-58268422</phone>
      <email>trdrug@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tongren Hospital</investigator_affiliation>
    <investigator_full_name>Xiuli Zhao</investigator_full_name>
    <investigator_title>Director of Phase I Clinical Trial Center</investigator_title>
  </responsible_party>
  <keyword>Azithromycin eye drops</keyword>
  <keyword>Local Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

